![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
ABSTRACT
Seven hypertensive patients receiving the dihydropyridine calcium channel blocking agent nicardipine were given placebo, 6.25, 12.5, 25 and 50 mg hydrochlorothiazide (HCTZ) in a randomized crossover design. Blood pressure (BP) decreased by about 7/3 mmHg irregardless of dose. In contrast, potassium, glucose and uric acid increased in a dose-dependent fashion. The hypokalemic and hyperglycemic responses at 50 mg were larger than usually seen with HCTZ. Low doses of HCTZ provided a modest antihypertensive effect, but 25 and 50 mg of HCTZ were no more effective in lowering BP and gave unusually large metabolic side effects when combined with a calcium channel blocker.